MA54452A - Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a - Google Patents

Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Info

Publication number
MA54452A
MA54452A MA054452A MA54452A MA54452A MA 54452 A MA54452 A MA 54452A MA 054452 A MA054452 A MA 054452A MA 54452 A MA54452 A MA 54452A MA 54452 A MA54452 A MA 54452A
Authority
MA
Morocco
Prior art keywords
inhibitors
derivatives used
methionine adenosyltransferase
oxoquinazoline derivatives
oxoquinazoline
Prior art date
Application number
MA054452A
Other languages
English (en)
Inventor
Muzaffar Alam
Leah Cleary
Melissa Fleury
John E Knox
Zachary E R Newby
Zhonghua Pei
Richard Steel
James Sutton
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of MA54452A publication Critical patent/MA54452A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054452A 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a MA54452A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777715P 2018-12-10 2018-12-10
US201962835853P 2019-04-18 2019-04-18
US201962883945P 2019-08-07 2019-08-07

Publications (1)

Publication Number Publication Date
MA54452A true MA54452A (fr) 2022-03-16

Family

ID=69138003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054452A MA54452A (fr) 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Country Status (17)

Country Link
US (5) US12503467B2 (fr)
EP (1) EP3894396A1 (fr)
JP (2) JP7688578B2 (fr)
KR (1) KR20210103498A (fr)
CN (2) CN119528824A (fr)
AU (1) AU2019395338B2 (fr)
BR (1) BR112021010842A2 (fr)
CA (1) CA3121236A1 (fr)
CL (1) CL2021001508A1 (fr)
CO (1) CO2021008895A2 (fr)
IL (1) IL283743B1 (fr)
MA (1) MA54452A (fr)
MX (1) MX428281B (fr)
PH (1) PH12021551274A1 (fr)
SG (1) SG11202105469YA (fr)
TW (1) TWI863945B (fr)
WO (1) WO2020123395A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (fr) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
AU2021228284A1 (en) * 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
UA130412C2 (uk) * 2020-06-22 2026-02-11 Ф. Хоффманн-Ля Рош Аг Похідні сульфону
EP4168394A1 (fr) * 2020-06-22 2023-04-26 F. Hoffmann-La Roche AG Dérivés d'amidopyrimidone
WO2021254529A1 (fr) * 2020-07-14 2021-12-23 江苏先声药业有限公司 Composé bicyclique
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (fr) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. Formes cristallines d'un inhibiteur de kras g12c
EP4216951B1 (fr) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
MX2023005823A (es) * 2020-11-20 2023-05-31 Amgen Inc Procedimiento para preparar 7-cloro-6-fluoro-1-(2-isopropil-4-meti lpiridin-3-il)pirido[2,3-d]pirimidino-2,4(1h,3h)-diona.
EP4262807A4 (fr) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
WO2022133038A1 (fr) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras de tétrahydropyridopyrimidine
WO2022143864A1 (fr) 2020-12-31 2022-07-07 江苏先声药业有限公司 Composé tricyclique et son utilisation
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (fr) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 Composé pyrimidone et son utilisation
CN117295734A (zh) * 2021-04-30 2023-12-26 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
US20240269143A1 (en) * 2021-06-02 2024-08-15 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor
JP7721686B2 (ja) * 2021-06-02 2025-08-12 南京正大天晴制薬有限公司 メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
IL308853A (en) * 2021-06-02 2024-01-01 Ideaya Biosciences Inc Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
CN118434722A (zh) * 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
US20250090533A1 (en) * 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
CN118414338A (zh) 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
WO2023177894A1 (fr) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un agent antimétabolite
US20250221979A1 (en) 2022-03-29 2025-07-10 Shouyao Holdings (beijing) Co., Ltd. Novel heterocyclic compound
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
CN116903613A (zh) * 2022-04-20 2023-10-20 深圳微芯生物科技股份有限公司 2-氧代喹唑啉并五元杂环衍生物、其制备方法及其应用
AU2023299635A1 (en) * 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
EP4582423A1 (fr) 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Nouveau composé dérivé tricyclique et ses utilisations
TW202440126A (zh) 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
WO2024118943A2 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt5
AU2022489881A1 (en) * 2022-11-30 2025-06-19 Ideaya Biosciences, Inc. 2-oxoquinazoline crystalline forms
WO2024118830A1 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Atropisomères d'inhibiteurs de mat2a
CN117777134B (zh) * 2022-12-19 2025-02-25 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
AU2024258943A1 (en) * 2023-04-19 2025-10-30 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof
CN120981449A (zh) * 2023-04-19 2025-11-18 英矽智能科技知识产权有限公司 结晶性甲硫氨酸腺苷转移酶2a (MAT2A)抑制剂及其用途
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
WO2024255802A1 (fr) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 Sel et forme cristalline d'un inhibiteur hétérocyclique de la méthionine adénosyltransférase-2a et procédé de préparation correspondant
CN116478172B (zh) * 2023-06-20 2023-09-05 英矽智能科技(上海)有限公司 吡咯并[3,2-d]嘧啶类化合物及其应用
IL327063A (en) 2023-09-15 2026-05-01 Ideaya Biosciences Inc Methods for treating MAT2A-related diseases
WO2025064750A1 (fr) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Polythérapie avec un inhibiteur de parg
WO2025072544A1 (fr) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Composés de sulfonamino indazole utilisés en tant qu'inhibiteurs de parg
WO2025166260A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino tricycliques substitués par un amide utilisés en tant qu'inhibiteurs de prmt5
WO2025166215A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino trihétérocycliques utilisés en tant qu'inhibiteurs de prmt5
WO2025166229A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés amidino tricycliques utilisés en tant qu'inhibiteurs de prmt5
WO2025166257A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino trihétérocycliques substitués par un amide utilisés en tant qu'inhibiteurs de prmt5
WO2025166274A1 (fr) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Composés guanidino tricycliques utilisés en tant qu'inhibiteurs de prmt5
CN120842232A (zh) * 2024-04-26 2025-10-28 中国科学院上海药物研究所 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途
WO2025250569A1 (fr) 2024-05-29 2025-12-04 Amgen Inc. Traitements du cancer utilisant des inhibiteurs de prmt5 mta-coopératifs et des inhibiteurs de mat2a
CN118724899B (zh) * 2024-07-03 2025-09-30 中国药科大学 2(1h)-喹喔啉酮化合物、其药物组合物及应用
CN122036626A (zh) * 2024-11-15 2026-05-15 上海青润医药科技有限公司 嘧啶-2(1h)-酮衍生物、其药物组合物及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202661A (en) 1962-11-27 1965-08-24 Hoffmann La Roche Substituted 3-amino 4-phenyl quinolones
US4096144A (en) 1970-12-08 1978-06-20 Sumitomo Chemical Company, Limited Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives
JPS5761758B2 (fr) 1974-01-11 1982-12-25 Hisamitsu Pharmaceutical Co
CA2146126A1 (fr) 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composes pharmaceutiques inhibant la production du facteur de necrose des tumeurs
US5874519A (en) 1994-05-11 1999-02-23 Asahi Kasei Kogyo Kabushiki Kaisha Para-oriented aromatic polyamide shaped articles and preparation thereof
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
JP2001513560A (ja) 1997-08-28 2001-09-04 ブリストル−マイヤーズ スクイブ カンパニー ４−アリール−３−アミノキノリン−２−オン誘導体カリウムチャンネル調節剤
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2004065542A2 (fr) 2002-12-30 2004-08-05 Exelixis, Inc. Mat2a utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2005020885A2 (fr) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)
US7049309B2 (en) 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8722580B2 (en) 2006-11-22 2014-05-13 Sumitomo Chemical Company, Limited Agent for inhibiting cytokinin signaling
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2266984A1 (fr) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines en tant qu' antagoniste du Wnt pour le traitement du cancer et de l'arthrite
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
US8835458B2 (en) * 2010-08-31 2014-09-16 Hanmi Science Co., Ltd Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
CA2826034A1 (fr) 2011-01-28 2012-08-02 University Of Kentucky Research Foundation Analogues de stilbene et procedes de traitement du cancer
EP2721179A4 (fr) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L Compositions de biomarqueur et procédés associés
JP2014528410A (ja) 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
RU2014129740A (ru) * 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
CN102816197B (zh) 2012-08-24 2015-04-29 四川大学华西医院 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
WO2017096165A1 (fr) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
AU2017300336B2 (en) 2016-07-18 2021-03-11 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
UA125852C2 (uk) * 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
SG11201901775SA (en) 2016-09-02 2019-03-28 Futurevault Inc Real-time document filtering systems and methods
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
EP3630749B9 (fr) * 2017-05-26 2024-05-29 Cancer Research Technology Limited Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
WO2018221433A1 (fr) 2017-05-29 2018-12-06 第一三共株式会社 Dérivé d'amine hétéroaryle
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
HUE066282T2 (hu) 2018-03-30 2024-07-28 Servier Lab Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11376256B2 (en) 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
EP3887373A1 (fr) * 2018-11-29 2021-10-06 Araxes Pharma LLC Composés et procédés d'utilisation associés pour le traitement du cancer
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
AU2019414446A1 (en) 2018-12-27 2021-07-15 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
US12077534B2 (en) 2018-12-27 2024-09-03 Les Laboratoires Servier Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
US20230227409A1 (en) 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040B1 (fr) 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. Dérivés de 2-aminoquinazolinone comme inhibiteurs de la méthionine adénosyltransférase 2a
US20240208965A1 (en) 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (fr) 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. Dérivés de 4-arylquinazoline en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
TW202227082A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
KR20230065238A (ko) 2020-09-11 2023-05-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치, 표시 모듈, 및 전자 기기
IL308853A (en) 2021-06-02 2024-01-01 Ideaya Biosciences Inc Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
US20250090533A1 (en) 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
US20250243188A1 (en) 2022-04-08 2025-07-31 Ideaya Biosciences, Inc. Methionine adenosyltranserase 2a inhibitors
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
WO2024118830A1 (fr) 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Atropisomères d'inhibiteurs de mat2a

Also Published As

Publication number Publication date
IL283743B1 (en) 2026-07-01
TWI863945B (zh) 2024-12-01
EP3894396A1 (fr) 2021-10-20
JP2022512156A (ja) 2022-02-02
US20260217709A1 (en) 2026-07-30
IL283743A (en) 2021-07-29
PH12021551274A1 (en) 2021-12-06
CO2021008895A2 (es) 2021-07-30
JP7688578B2 (ja) 2025-06-04
WO2020123395A1 (fr) 2020-06-18
JP2025116052A (ja) 2025-08-07
AU2019395338B2 (en) 2025-11-13
US11046691B1 (en) 2021-06-29
TW202039487A (zh) 2020-11-01
CN113166078A (zh) 2021-07-23
US20220106276A1 (en) 2022-04-07
AU2019395338A1 (en) 2021-07-29
SG11202105469YA (en) 2021-06-29
CL2021001508A1 (es) 2022-01-21
CA3121236A1 (fr) 2020-06-18
CN113166078B (zh) 2024-11-19
MX2021006841A (es) 2021-07-02
US11130759B1 (en) 2021-09-28
KR20210103498A (ko) 2021-08-23
US11084798B1 (en) 2021-08-10
BR112021010842A2 (pt) 2021-08-24
MX428281B (es) 2025-11-13
CN119528824A (zh) 2025-02-28
US12503467B2 (en) 2025-12-23

Similar Documents

Publication Publication Date Title
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
EP4038058A4 (fr) Dérivés de cannabinoïdes
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine